Medicenna Therapeutics is a clinical-stage immunotherapy company developing engineered cytokines, called Superkines, designed to improve the specificity, function, and safety profile of unmodified interleukins. Medicenna owns diverse platforms licensed from Stanford University to develop a pipeline of Superkine candidates: interleukin-2 (IL-2), IL-4 and IL-13 super-agonists and antagonists. MDNA11, a potential best-in-class, next-generation IL-2 super agonist targeting solid tumors, is currently in a Phase 2 monotherapy dose expansion trial and expected to begin a Phase 2 pembrolizumab combination trial in the fourth quarter of 2023. Medicenna’s IL-4-empowered Superkine, bizaxofusp (MDNA55), has completed a Phase 2b trial for recurrent glioblastoma and holds FastTrack and Orphan Drug status from the U.S. Food and Drug Administration (FDA) and FDA/European Medicines Agency, respectively. Medicenna also creates Bifunctional SuperKine Immunotherapies (BiSKITs), which have demonstrated superior anti-tumor activity in preclinical studies, even in hard-to-treat ‘cold’ tumors. For more information, please visit https://www.medicenna.com/.
Company profile
Ticker
MDNAF, MDNA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
MDNAF stock data
Latest filings (excl ownership)
6-K
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
26 Apr 24
6-K
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
25 Apr 24
AW
Withdrawal of amendment
22 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 24
F-3/A
Shelf registration (foreign) (amended)
16 Apr 24
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
16 Apr 24
6-K
Current report (foreign)
9 Apr 24
6-K
Current report (foreign)
9 Apr 24
6-K
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
4 Apr 24
6-K
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
6 Mar 24
Transcripts
Financial summary
Quarter (USD) | Mar 23 | Mar 22 | Mar 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
26.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 29 |
Opened positions | 3 |
Closed positions | 1 |
Increased positions | 4 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 4.07 bn |
Total shares | 18.47 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Merchant Fahar | 5.50 mm | $0.00 |
Hirschman Orin | 4.35 mm | $0.00 |
AIGH Capital Management | 4.34 mm | $2.09 bn |
Worth Venture Partners | 1.09 mm | $524.50 mm |
Hudson Bay Capital Management | 780.56 k | $373.89 mm |
DAFNA Capital Management | 660.00 k | $317.92 mm |
Verition Fund Management | 589.50 k | $282.37 mm |
Sigma Planning | 305.30 k | $147.06 mm |
Letko, Brosseau & Associates | 120.00 k | $57.80 mm |
RY Royal Bank Of Canada | 118.76 k | $57.00 mm |
Press releases
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
10 Apr 24
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
9 Apr 24
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
9 Apr 24
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
14 Feb 24
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
13 Feb 24